OCEANSIDE, CA -- (Marketwire) -- 12/03/12 -- Therapeutic Solutions International, Inc. (OTCQB: TSOI), announced today that it has recently completed all of its regulatory filings required by the Securities and Exchange Commission, and that it is now 'fully reporting' and compliant.

Tim Dixon, CEO of Therapeutic Solutions International, Inc., stated, "We are elated to have achieved this milestone for the company. As a result, TSI has been upgraded to a higher tier on OTCMarkets.com, (the "OTCQB Market Tier"), hence allowing investors access to timely information and liquidity.

In addition, we are very excited to begin the international launch of our key products Migran-X™ and AMPSA CS™ globally. We will be updating the investment community frequently over the weeks ahead with our anticipated progress."

Therapeutic Solutions International is a global manufacturer of the chairside anterior midpoint stop appliance (AMPSA) devices marketed internationally under the trade names Migran-X™ and AMPSA CS™, which has helped countless patients prevent debilitating migraine and tension headache pain, bruxism, clenching, grinding, and TMJ disorders. The Migran-X™ and AMPSA CS™ devices are the most effective non-drug FDA cleared method of migraine prevention on the market today. The AMPSA is a device that a dentist fits on a patient for the treatment of medically diagnosed migraine pain, as well as migraine associated tension-type headaches, by reducing their signs and symptoms through the reduction of trigeminally innervated muscular activity, and for the prevention of bruxism and TMJ syndrome through the reduction of trigeminally innervated muscular activity.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International, Inc. produces and markets the FDA cleared NTI Tension Suppression System devices sold in the United States under the tradename NTI-tss®, and internationally as the Migran-X™ and AMPSA CS™ for the prevention of medically diagnosed migraine pain. The device is the most cost effective, non-drug method of migraine prevention on the market today. We also license laboratories to manufacture and sell semi-custom AMPSA devices internationally. Our corporate website is www.therapeuticsolutionsint.com.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to the need for further financing, our exit from the US market for AMPSA products in 2013, the need to procure additional international distributors, direct competition beginning in 2013, reliance on key personnel, possible introduction of new product lines, and other specific risks set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.